ArticleJournal of xenobiotics2026
Comparative In Vitro Response of HaCaT and A375 Melanoma Cells to Zinc Oxide Nanoparticles Synthesized Using Puerarin.
Article in Journal of xenobiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preclinical Evaluation of Labetalol for Cutaneous Melanoma Drug Repurposing: Cytotoxic Activity in A375 Cells and Mitochondria-Associated Apoptotic Signaling.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc oxide nanobiocomposites were successfully synthesized using a green synthesis approach based on the isoflavone Puerarin, resulting in the formation of PUE-ZnO NPs. Building on their previous physicochemical and in ovo characterization, the present study aimed to comparatively evaluate the biological response induced by PUE-ZnO NPs in non-tumorigenic HaCaT keratinocytes and A375 melanoma cells. Cell viability was assessed by MTT assay, and the cellular response was further investigated through bright-field morphological evaluation, Hoechst 33342 nuclear staining, MitoTracker mitochondrial staining, and clonogenic assay. PUE-ZnO NPs showed a favorable cytocompatibility profile in HaCaT cells, with viability remaining above 80% at the highest tested concentration and only moderate impairment of clonogenic capacity at higher concentrations. In contrast, A375 melanoma cells exhibited a stronger response, characterized by reduced viability, marked morphological alterations, nuclear changes, mitochondrial staining disruption, and a pronounced decrease in colony-forming ability. PUE-ZnO NPs may represent a promising phytochemical-assisted ZnO-based nanosystem for further investigation in melanoma-related models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.